Expert Interview
Discussing TNBC and the potential of G1 Therapeutics' trilaciclib with a focus on the PRESERVE 2 trial
Ticker(s): GTHXInstitution: Peter MacCallum Cancer Center
- Medical oncologist and clinician scientist with a decade of experience in breast cancer management, clinical trials, precision oncology, and translational research
- Interests include immune microenvironment, single cell approaches, multi-omics, rapid autopsy programs and AI
- PI on multiple clinical trials and international steering commitee membership.
Roughly how many patients with TNBC do you manage?
Added By: c_adminOn a scale from 1-10, 10 being extremely excited (where would you rate your level of excitement for trilaciclib?
Added By: c_adminCould increased exposure to Gem/Carbo doublet therapy in the first line setting positively impact survival?
Added By: sks144Do you find the theory around T-cell expansion plausible for explaining the excellent results in the P2 TNBC trial or are you skeptical?
Added By: usere49138a8Does the recent data release for the open label trial combining Cosela and Trodelvy in 2L TNBC increase your confidence level for a positive outcome in the P3 TNBC trial?
Added By: usere49138a8Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
